SCHEMBL3485976

SCHEMBL3485976

C#CC[C@]1(n2cc(N)c(=O)[nH]c2=O)C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O1

nearest known ligand 0.41

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
P2RY6 Q15077 9/20 0.41
P2RY2 P41231 7/20 0.41
POLA1 P09884 2/20 0.40
POLB P06746 1/20 0.40
POLD1 P28340 1/20 0.40
P2RY4 P51582 5/20 0.39
P2RX3 P56373 1/20 0.36
DTYMK P23919 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4010795 0.87 P2RY6 (0.41) P2RY6P2RY2POLA1POLBPOLD1
SCHEMBL886859 0.85 POLG (0.41) P2RY6P2RY2P2RY4P2RX3
SCHEMBL6514738 0.84 P2RY2 (0.44) P2RY6P2RY2POLA1POLBPOLD1
SCHEMBL5191085 0.81 POLB (0.50) P2RY6P2RY2POLA1POLBPOLD1
SCHEMBL7760372 0.81 TK1 (0.35)
SCHEMBL5708922 0.80 POLG (0.48) P2RY6P2RY2POLBP2RY4
SCHEMBL5285301 0.77 POLB (0.48) P2RY6P2RY2POLA1POLBPOLD1
SCHEMBL5188713 0.76 POLB (0.45) P2RY6P2RY2POLA1POLBPOLD1
SCHEMBL7520080 0.76 P2RY2 (0.35) P2RY6P2RY2POLA1P2RY4P2RX3
SCHEMBL3715513 0.76 POLB (0.51) P2RY6P2RY2POLA1POLBPOLD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050214759-A1 Enzymatic redox labelling of nucleic acids WLASSOF WJATSCHESSLAW 2005-09-29 US claimed
EP-1468006-A1 ENZYMATIC REDOX LABELLING OF NUCLEIC ACIDS UNISEARCH LIMITED (AU) 2004-10-20 EP claimed
WO-2003055898-A1 ENZYMATIC REDOX LABELLING OF NUCLEIC ACIDS UNISEARCH LIMITED (AU) 2003-07-10 WO claimed
US-12584168-B2 Sample preparation method OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-03-24 US disclosed
US-20250313889-A1 SAMPLE PREPARATION METHOD OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2025-10-09 US disclosed
US-20230250474-A1 SAMPLE PREPARATION METHOD OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2023-08-10 US disclosed
US-11542551-B2 Sample preparation method OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2023-01-03 US disclosed
US-20200318179-A1 SAMPLE PREPARATION METHOD OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2020-10-08 US disclosed
US-10669578-B2 Sample preparation method OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2020-06-02 US disclosed
EP-3108010-B1 SAMPLE PREPARATION METHOD OXFORD NANOPORE TECH LTD (GB) 2018-11-28 EP disclosed
EP-1725572-B1 MACROMOLECULAR NUCLEOTIDE COMPOUNDS AND METHODS FOR USING THE SAME AGCT GMBH (DE) 2017-05-31 EP disclosed
US-20100093992-A1 Macromolecular Nucleotide Compounds and Methods for Using the Same PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2010-04-15 US disclosed
US-20100029494-A1 Macromolecular Nucleotide Compounds And Methods For Using The Same PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2010-02-04 US disclosed
EP-2074133-A2 COMPONENTS AND METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEIC ACIDS Genovoxx GmbH (DE) 2009-07-01 EP disclosed
WO-2008043426-A2 COMPONENTS AND METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEIC ACIDS GENOVOXX GMBH (DE) 2008-04-17 WO disclosed
EP-1885876-A2 MACROMOLECULAR NUCLEOTIDE LINKS AND METHODS FOR THEIR USE Genovoxx GmbH (DE) 2008-02-13 EP disclosed
EP-1725572-A2 MACROMOLECULAR NUCLEOTIDE COMPOUNDS AND METHODS FOR USING THE SAME Genovoxx GmbH (DE) 2006-11-29 EP disclosed
WO-2006097320-A2 MACROMOLECULAR NUCLEOTIDE LINKS AND METHODS FOR THEIR USE GENOVOXX GMBH (DE) 2006-09-21 WO disclosed
US-20050214759-A1 Enzymatic redox labelling of nucleic acids WLASSOF WJATSCHESSLAW 2005-09-29 US disclosed
WO-2005044836-A2 MACROMOLECULAR NUCLEOTIDE COMPOUNDS AND METHODS FOR USING THE SAME GENOVOXX GMBH (DE) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12584168-B2 Sample preparation method POLN, POLRMT, POLM P2RY6 259/4885P2RY2 181/4885POLA1 19/4885
US-20100093992-A1 Macromolecular Nucleotide Compounds and Methods for Using the Same NCL, PNP, NUDT1 P2RY6 832/4885P2RY2 941/4885POLA1 110/4885
US-20100029494-A1 Macromolecular Nucleotide Compounds And Methods For Using The Same DUT, SAMHD1, PNP P2RY6 1071/4885P2RY2 1513/4885POLA1 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.